Showing results (81-90 of 114) with videos related to
Sort By:
Pageof 12
BMC Cancer|December 3, 2021
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsLuis Teixeira, Jacques Medioni, Julie Garibal, et al.Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.The Lancet. Oncology|December 3, 2014
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialKarim Fizazi, Lance Pagliaro, Agnes Laplanche, et al.European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.European Urology Oncology|October 24, 2024
Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line TreatmentPhilippe Barthélémy, Constance Thibault, Aude Fléchon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO StudyConstance Thibault, Mostefa Bennamoun, Aude Fléchon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.Pageof 12